24 February 2021 - ViiV Healthcare announced today the submission of a supplemental new drug application to the US FDA for ...
17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada. ...
16 February 2021 - Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined ...
1 February 2021 - It is the first extrafine fixed triple combination therapy in a single inhaler to be approved for ...
1 February 2021 - EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on a medicine known ...
26 January 2021 - FDA grants priority review of the application and sets a PDUFA target action date of 8 June ...
11 January 2021 - Aerie Pharmaceuticals today announced the European Commission has granted a marketing authorisation for Roclanda (netarsudil and latanoprost ...
29 December 2020 - Eyenovia today announced that it has submitted a new drug application to the U. S. FDA ...
28 December 2020 - Vertex Pharmaceuticals Incorporated today announced its New Drug Submission for Trikafta, Vertex’s investigational triple combination medicine, ...
21 December 2020 - Marketing authorisation granted by European Commission for ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to be used ...
21 December 2020 - More than 600 people with certain rare cystic fibrosis mutations are now eligible for Trikafta, Symdeko or ...
14 December 2020 - Fourth major approval for AstraZeneca’s triple-combination therapy which is marketed as Breztri Aerosphere in the US, ...
11 December 2020 - Advicenne today announces the CHMP of the EMA adopted a positive opinion recommending approval of its lead ...
27 November 2020 - The combination therapy is a new treatment option for CF patients who are homozygous for F508del. ...
13 November 2020 - European Commission Decision Anticipated in Approximately Two Months. ...